- Collaboration with Fairtility brings AI-powered embryo assessment capabilities to Esco Medical’s MIRI® TL incubator customers.
- Esco Medical continues to demonstrate its commitment to innovation by delivering cutting-edge solutions to IVF clinics and laboratories.
LITHUANIA, 20 January 2025 – Esco Medical is a proud partner of Fairtility, a MedTech company specialising in AI-powered IVF technologies. Through this collaboration, Esco Medical’s MIRI® TL incubators feature CHLOE™, Fairtility’s AI-powered software platform that provides transparent and predictive analyses of embryo and oocyte quality, while designed to enhance clinic efficiency and augment patient experience.
By integrating CHLOE™ into MIRI® TL, Esco Medical enables fully automated annotation and analysis, supporting embryologists in making data-driven decision, enhancing efficiency, and facilitating improved outcomes.
“Our partnership with Fairtility is a major first step in using AI to enhance Esco Medical products. By collaborating with innovative AI providers, we ensure continuous innovation while giving IVF clinics the flexibility to select solutions that align with their unique workflows, enabling personalized, patient-focused care.” said Domantas Armonavičius, Esco Medical Product Manager.
“AI has made remarkable progress in recent years and is now transitioning from early adoption to mainstream use,” said Eran Eshed, CEO and Co-Founder of Fairtility. “Our partnership with ecosystem leaders like Esco Medical enables us to sustain this momentum by delivering innovative, practical products and technologies, all with the ultimate goal of improving patient care.”
Esco Medical and Fairtility’s collaboration underscores the companies’ commitment to supporting IVF clinics in delivering better outcomes for patients. The CHLOE™ integrated MIRI® TL offers a clearer path to success, bringing hope and reassurance to families on their journey to parenthood.
